SHANGHAI, Mar 3, 2025 - (ACN Newswire via SeaPRwire.com) - On February 27th, the awarding ceremony of the second batch of Shanghai Innovative Enterprise Headquarters was held in Shanghai. Gong Zheng, Deputy Secretary of Shanghai Municipal Party Committee and Mayor of Shanghai, awarded the certificates to 49 innovative enterprise headquarters, and Hua Medicine was among them. Dr. Li Chen, the founder and CEO of the Company, went on stage to receive the award and delivered a speech as a representative of the enterprises.(Gong Zheng, Deputy Secretary of Shanghai Municipal Party Committee andMayor of Shanghai, awarded the titles to innovative enterprise headquarters)Innovative enterprises are an important part of Shanghai's modern industrial system and the source of vitality for Shanghai's high-quality development. In recent years, innovative enterprises in Shanghai have been growing and developing rapidly, having an obvious driving effect on the industry. The enterprises awarded this time are from key industrial fields such as integrated circuits, biomedicine, artificial intelligence, digital economy, and emerging strategic comprehensive industries. All the selected enterprises exhibit the characteristics of strong innovation leadership, vigorous development vitality, and obvious agglomeration development. (Certificate of innovative enterprise headquarters)Hua Medicine, headquartered in Shanghai but with a global outlook, is leveraging China's evolving pharmaceutical regulatory landscape and the innovative drug full-chain industrial environment such as the pharmaceutical research and development, production, and business environment created by Shanghai to continuously accelerate the transformation and implementation of innovative achievements. Hua Medicine took ten years to develop a globally first-in-class and national Class I new drug, glucokinase activator (GKA) dorzagliatin (Trade name:) independently, which was first launched in China, with a globally new target and a new mechanism.In September 2022, dorzagliatin was approved for marketing by the National Medical Products Administration of China for the treatment of type 2 diabetes. It is the first GKA approved for marketing worldwide and has also become the tenth class of diabetes treatment drugs recognized by the World Health Organization (WHO). By the end of 2023, dorzagliatin was successfully included in China's National Reimbursement Drug List (NRDL), greatly improving the accessibility and affordability of this innovative drug for patients.As a global innovation leader in the GKA field, Hua Medicine has received national-level awards on multiple occasions during the research and development period and after the product launch, and has undertaken major national projects. These include being consecutively selected as a major new drug development special project under the "12th Five-Year Plan" and the "13th Five-Year Plan” by the Ministry of Science and Technology, and winning the First Prize of the Science and Technology Award of the Chinese Pharmaceutical Association, among others. Currently, Hua Medicine is actively carrying out the development of the second-generation GKA and fixed combination preparations, aiming to bring more innovative and good drugs to patients in China and even globally in the fields of diabetes and its complications, such as obesity and diabetic nephropathy. (Dr. Li Chen delivered a speech as a representative of the enterprises)As a representative of the enterprises, Dr. Li Chen said in his speech at the awarding ceremony: "Coinciding with the new era and new journey of Shanghai accelerating the construction of a scientific and technological innovation center and fully promoting the upgrading and development of strategic emerging industries, Hua Medicine being recognized as the Shanghai Innovative Enterprise Headquarters is an affirmation of the enterprise's past and also an encouragement and inspiration for the enterprise's future development. Hua Medicine will continue to leverage its advantages of conceptual innovation, technological innovation, and model innovation, keep making progress, and contribute to the construction of Shanghai's scientific and technological innovation center and the innovative development of the biomedicine industry."Receiving the title of "Shanghai Innovative Enterprise Headquarters" this time is not only an honor for Hua Medicine but also a responsibility and mission. In the future, taking this as an opportunity, Hua Medicine will continuously increase its innovation investment and the ability of achievement transformation, continuously enhance its international competitiveness, provide more high-quality innovative drugs and treatment solutions for patients, help Shanghai's biomedicine industry reach new heights, and promote the construction of the "Healthy China" strategy.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsE-mail: ir@huamedicine.comMediaEmail: pr@huamedicine.com Copyright 2025 ACN Newswire via SeaPRwire.com.
HONG KONG, Mar 3, 2025 - (ACN Newswire via SeaPRwire.com) - Nissin Foods (Hong Kong) Charity Fund (“Charity Fund”) announced its continued support for outstanding food and nutritional sciences students from The Chinese University of Hong Kong (“CUHK”) for the third consecutive year. The 2024-2025 Nissin Foods Scholarship Presentation Ceremony was held today to present scholarships to 13 undergraduate and postgraduate students, who strive for excellence in their academic performance and aspire to become future industry leaders.Established by the Charity Fund and CUHK in 2022, the scholarship will cover their full tuition fees for the academic year, and is renewable, subject to annual performance review, with the intent to support the students throughout their study period, so that they can focus on their studies without worrying about financial burdens. The four new awardees for the 2024-2025 academic year are: LEUNG Hau Man, LO Chun Hei and WONG Siu Yu from CUHK’s Bachelor of Science in Food and Nutritional Sciences programme, and ZHOU Zhengming from the PhD programme. The nine renewed awardees are LAM Tsz Hang, SHUM Wai Hang, CHAN Hoi Yi, HSU Po Ling, KWAN Ka Yi, LAM Shuk Fan and WONG Wai Yee from the Bachelor’s degree programme, and ZHOU Dandan, LIN Yuhong from the PhD programme. Mr. Kiyotaka ANDO, Chairman of Nissin Foods (Hong Kong) Charity Fund, said, "At Nissin Foods, we believe that food-related jobs are sacred professions. They serve both life and society. We share the values with The Chinese University of Hong Kong in nurturing outstanding and caring food professionals, who will contribute to Hong Kong's development. By empowering students studying food and nutritional sciences in CUHK and elite athletes aspiring to become teachers from the Education University of Hong Kong, we promote a healthy lifestyle through food and sports. This reflects the vision of our founder, Mr. Momofuku Ando, who said, ‘Eating and sports are the two axles of health."Professor Anthony CHAN, Pro-Vice-Chancellor and Vice-President of The Chinese University of Hong Kong, expressed his genuine gratitude for the generous support of the Charity Fund to CUHK, said, "Mr. Momofuku Ando, the Founder of Nissin Foods, was a visionary leader who dedicated himself to serve our society through technological innovation and had the courage to create positive change in our lives. His spirit continues to inspire many of us. CUHK has all along been committed to providing fertile ground for nurturing the future leaders of our society. We feel privileged that our vision in advancing higher education has been shared by Nissin Foods."Ms. WONG Wai Yee, on behalf of all the scholarship recipients, thanked the Charity Fund and CUHK for setting up the scholarship scheme and presented a booklet of appreciation from the 13 awardees to Mr. Kiyotaka ANDO. She said, "This scholarship empowers us to pursue our passions and aspirations in the realm of food and nutrition without constraints. As Nissin Foods Scholars, we are driven by a spirit of innovation to contribute to solutions for a secure and healthy global food supply, ensuring that the benefits of food and nutrition reach every corner of the world."PhotoMr. Kiyotaka ANDO, Chairman of Nissin Foods (Hong Kong) Charity Fund (middle right), and Professor Anthony CHAN, Pro-Vice-Chancellor and Vice-President of CUHK (middle left), attended the 2024-2025 Nissin Foods Scholarship Presentation Ceremony today. There are 13 scholarship recipients for the 2024-2025 academic year. The four new awardees this year are (front, from left to right) LEUNG Hau Man, LO Chun Hei and WONG Siu Yu from CUHK’s Bachelor of Science in Food and Nutritional Sciences programme, and ZHOU Zhengming from the PhD programme. The nine renewed awardees are: (back, from left to right) LAM Tsz Hang, SHUM Wai Hang, ZHOU Dandan, CHAN Hoi Yi, HSU Po Ling, KWAN Ka Yi, LAM Shuk Fan and WONG Wai Yee, and LIN Yuhong from the Bachelor’s degree or the PhD programme.About Nissin Foods (Hong Kong) Charity FundThe Nissin Foods (Hong Kong) Charity Fund (“Charity Fund”) was set up in September 2020 by way of a trust deed by Nissin Foods Company Limited (Stock code: 1475). The objectives of the Charity Fund are: a) to advance education, teaching, learning, arts, science and academic research; b) to make provision for people in need; and c) to carry out works of a charitable nature that are beneficial to the Hong Kong community. Copyright 2025 ACN Newswire via SeaPRwire.com.
SOLANA BEACH, CA, Mar 4, 2025 - (ACN Newswire via SeaPRwire.com) - American Wave Machines, the global leader in world-class surf pool destinations, has begun commissioning PerfectSwell® in the heart of Brazil's vibrant financial center São Paulo. AWM has partnered with JHSF, Brazil's leading high-end real estate development company, on their second PerfectSwell® location, the São Paulo Surf Club. With the iconic Ponte Estaiada bridge as a backdrop, top Brazilian Pros Italo Ferreira and Miguel Pupo, along with AWM's Rob Kelly, put the latest PerfectSwell® innovations through the paces. Commissioning will be completed in March."Our team has done an incredible job. Improvements in PerfectSwell® efficiency, performance, and maintainability are ongoing along with continuing wave design innovations. A lot of R & D went into maintaining ride length and guest beach space in a totally unique footprint," said Bruce McFarland, CEO and Founder of AWM. "The effort has paid off and PerfectSwell® is working great. It's an unsurpassed surf experience."Rob Kelly takes to the air at the newest PerfectSwell® pool in São Paulo. Photo Courtesy of Bruno Zanin.WSL Surfer Miguel Pupo said "It's a mind-blowing experience to surf in the heart of the city in another incredible JHSF venue design. There's so much power in these waves. We surfed the McFly, an incredible air section, and the other new waves, they're all addicting. I can't get myself to get out of the water.""This is the fifth PerfectSwell® commissioning I've been a part of and it's easily the most iconic destination created yet. There are several improvements that have exceeded expectations including our newest wave energy dampening system," said Miquel Lazaro Cordero, lead engineer at AWM. "These improvements have made it possible for us to bring our highest performance surf in this dense urban environment."São Paulo Surf Club with the city's iconic Ponte Estaiada bridge as backdrop. Photo Courtesy of JHSF.About American Wave MachinesAmerican Wave Machines, Inc. is the inventor and developer of PerfectSwell® Surf Technology. AWM's technology powers world class surf facilities and destinations backed by proven financials, extensive data capture, and stoked surfers. PerfectSwell® is the only sequence based, pneumatic surf technology on the market. Protected by over 50 patents worldwide, PerfectSwell® Split Peaks, Peeling Waves, Air Sections, and Wedge Barrels are all covered by AWM's robust patent portfolio.About JHSFJHSF is a Brazil-based holding company and leader in the high-income real estate industry in Brazil, engaged in real estate development, shopping mall and fashion retail and hospitality and gastronomy. Founded in 1972, the company's main area of operation and investment is in the high-income segment, with a focus on recurring income activities. The company, which has been publicly traded since 2007 and has its shares listed on B3's Novo Mercado, operates in both the Brazilian market and other countries, such as the United States and Uruguay. It was the first company in the Brazilian real estate sector to prioritize recurring income assets, including the operation of shopping centers, an airport, and hotels, in addition to real estate projects. For more information visit jhsf.com.brContact:Jenna Timinskyinfo@americanwavemachines.comSOURCE: American Wave Machines, Inc. Copyright 2025 ACN Newswire via SeaPRwire.com.
SAN DIEGO, CA, Mar 4, 2025 - (ACN Newswire via SeaPRwire.com) - General Atomics Aeronautical Systems, Inc. (GA-ASI) achieved another major milestone in the development of Unmanned Combat Air Vehicles (UCAVs) by flying U.S. government-provided autonomy software aboard a company-owned MQ-20 Avenger®. The demonstration was part of the Air Force Test Center's all-domain test series called Orange Flag 25-1, which took place Feb. 19-21 at Edwards Air Force Base, California.The demonstration included the use of a government-provided Pilot Vehicle Interface (PVI), showcasing GA-ASI's commitment to advancing its UCAV ecosystem through collaboration with partners and government entities and integrating cutting-edge technologies. Avenger is a jet-powered UAS used extensively by GA-ASI as a test bed for future Autonomous Collaborative Platforms.GA-ASI also demonstrated the ability to rapidly swap between autonomy systems midflight over Proliferated Low Earth Orbit (PLEO) satellites utilizing an autonomy product from Shield AI.Orange Flag 25-1 is part of the larger Orange Flag Evaluation and Demonstration Event series. This event brought together various stakeholders to test and validate advanced aerospace technologies in realistic operational scenarios.The government-provided autonomy software - known as a reference autonomy stack - was integrated into the GA-ASI Avenger and demonstrated autonomous flight operation capabilities focused on conducting air-to-air engagements. The government-provided PVI enabled seamless control and monitoring of the autonomy stack, highlighting the interoperability and flexibility of GA-ASI's UCAV ecosystem. The Shield AI stack demonstrated autonomy skills for safe administrative phases of flight.What the flights proved was that GA-ASI aircraft can quickly go from company-written software, to government-provided, to other vendors' software as needed. This reinforces that the new generations of GA-ASI's UCAVs can seamlessly get upgrades as fast as developers finish them. Just as a mobile phone can get new and better features with each update, so too can new UCAVs get more capable and more versatile."This demonstration marks a significant achievement in our ongoing efforts to operationalize autonomy for UCAVs," said GA-ASI Vice President of Advanced Programs Michael Atwood. "Flying the government reference autonomy stack at Orange Flag 25-1 and utilizing the government-provided PVI underscores our commitment to delivering robust and adaptable autonomy solutions for the warfighter. We especially appreciate and salute the support we received from the 309th Software Engineering Group."The successful flight at Orange Flag 25-1 further validates GA-ASI's dedication to maturing its open standards-based autonomy software ecosystem. By adhering to government-owned and maintained standards, GA-ASI ensures rapid integration of best-of-breed capabilities from third-party providers, enhancing the overall operational effectiveness of UCAV platforms.GA-ASI continues to demonstrate its commitment to advancing autonomy for UCAVs through a series of flight tests and collaborations with government and industry partners. These efforts are aimed at developing an autonomy infrastructure that enables rapid integration and validation of tactical software applications while maintaining safety of flight and providing warfighters with the most advanced capabilities possible. GA-ASI has been selected by the U.S. Air Force to build and fly the Collaborative Combat Aircraft (CCA).About GA-ASIGeneral Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable RPA systems, radars, and electro-optic and related mission systems, including the Predator® RPA series and the Lynx® Multi-mode Radar. With more than eight million flight hours, GA-ASI provides long-endurance, mission-capable aircraft with integrated sensor and data link systems required to deliver persistent situational awareness. The company also produces a variety of sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas.For more information, visit www.ga-asi.com.Avenger, Gray Eagle, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are trademarks of General Atomics Aeronautical Systems, Inc., registered in the United States and/or other countries.Contact InformationGA-ASI Media Relationsasi-mediarelations@ga-asi.comSOURCE: General Atomics Aeronautical Systems, Inc. Copyright 2025 ACN Newswire via SeaPRwire.com.
SANTA CLARA, CA, Mar 4, 2025 - (ACN Newswire via SeaPRwire.com) - Graid Technology, a leading innovator in GPU-based RAID for NVMe storage performance, today announced the successful closing of its $30 million Series B funding round. The round was led by HH-CTBC Partnership, a joint venture fund between Foxconn and CTBC, alongside Yuanta Ventures. The funding also includes participation from Delta Electronics Capital, Harbinger Venture Capital, and returning investors from Graid Technology's 2022 Series A round.Graid Technology Secures $30M Series B to Accelerate Growth in Data Storage & Protection MarketNew investments will drive expansion of Graid Technology’s industry-leading data protection solutions across OEM and Enterprise markets.This investment will drive global expansion, product innovation, and strategic partnerships, strengthening Graid Technology's presence in enterprise and OEM markets while meeting growing demand for AI, machine learning (ML), and high-performance computing (HPC) workloads.Graid Technology's SupremeRAID™ product line eliminates traditional RAID bottlenecks by offloading RAID operations to the GPU, maximizing NVMe SSD performance and scalability. With thousands of deployments worldwide, SupremeRAID™ is enabling data centers, AI research facilities, media production, and financial institutions to optimize storage infrastructure while ensuring data integrity, redundancy, and resilience."This funding marks a significant milestone, not only in expanding our market reach but also in driving new innovations," said Leander Yu, Founder and CEO of Graid Technology. "The backing of HH-CTBC Partnership, Yuanta Ventures, and other strategic investors reflects confidence in our vision. With their support, we are well-positioned to scale our technology and expand into new markets."About Graid TechnologyGraid Technology is transforming enterprise storage with SupremeRAID™, the world's first GPU-based RAID solution. By offloading RAID calculations to the GPU, SupremeRAID™ enables enterprises to maximize NVMe SSD performance, delivering unprecedented speed, efficiency, and scalability for AI, ML, media, and high-performance computing workloads. Headquartered in Silicon Valley, California, with an R&D center in Taipei, Taiwan, Graid Technology partners with leading OEMs and global technology providers to redefine NVMe storage performance.For more information, visit www.graidtech.com.Contact InformationAndrea EakenSenior Director of Marketing, Americas & EMEAandrea.eaken@graidtech.com949-742-9928SOURCE: Graid Technology Inc. Copyright 2025 ACN Newswire via SeaPRwire.com.
HO CHI MINH CITY, VIETNAM, Feb 27, 2025 - (ACN Newswire via SeaPRwire.com) - The 17th Annual Global CSR & ESG Summit 2025, themed "Scaling Impact and Redefining Value in Sustainability," came to a successful close yesterday at the Mai House Saigon Hotel. The event marked a significant milestone in the field of corporate social responsibility (CSR) and environmental, social, and governance (ESG) initiatives, attracting over 200 experts, practitioners, NGO representatives, and media partners.Hosted by The Pinnacle Group International in collaboration with the Sustainable Technology Centre, this year’s summit assembled industry leaders, policymakers, and subject matter experts to explore innovative ESG strategies and solutions to creating value for organisations and the community at large. The event showcased insightful discussions, on pressing issues including climate action, transition finance, carbon emissions, diversity and inclusion, ethical governance, and community engagement."Green Man" Matthias Gelber captivates the audience at The 17th Annual Global CSR & ESG Summit and Awards 2025 with his passionate keynote, urging businesses to embrace sustainable practices.Industry Leaders Convene to Drive Sustainability and ESG InnovationThe summit brought together top industry leaders and experts to explore solutions for achieving net-zero goals and advancing ESG initiatives. Mr. Mai Lam Dong, Cluster President of Schneider Electric Vietnam & Cambodia, emphasized the urgent need for carbon reduction technologies to achieve a sustainable future. He highlighted the role of smart grids, AI-driven energy management, and automation in enhancing efficiency and reducing emissions. By integrating renewables, microgrids, and electrification, businesses can accelerate the transition to a low-carbon economy. With Vietnam’s net-zero commitments, he called for stronger collaboration between industry, policymakers, and technology providers to scale these solutions for lasting environmental and economic impact.Building on this, Huang Yi Chun, Regional Leader for Climate Action & Sustainability at Gensler, shared how digital design is reshaping the built environment. He discussed AI-driven simulations and parametric design, suggesting ideas for businesses to integrate sustainability into urban planning and architecture to meet evolving regulatory demands.Prof. Dr. Geoffrey Williams, a leading economist and government advisor moderated a panel consisting of leaders from Bridgestone Asia Pacific, PT Hengjaya Mineralindo, and PT TBS Energi Utama where they shared insights on embedding ESG into workforce development, responsible resource management, and financing sustainable growth.Highlighting technology’s role in ESG transparency, Susanna Hasenoehrl, Head of Sustainability at SAP Asia, demonstrated how AI, big data, and blockchain are transforming sustainability reporting and corporate accountability in enabling faster and more accurate results.In another panel where strategic partnerships in sustainability were explored, Dr. Doseba Sinay of World Vision highlighted the transformative power of collaboration in addressing social and environmental challenges, emphasizing the need for multi-stakeholder engagement to create lasting impact. He shared how World Vision’s initiatives—ranging from reforestation and clean water access to livelihood programs—have been strengthened through corporate and government partnerships. Speakers from HEINEKEN Vietnam, Sarawak Energy Berhad, and Evermos echoed this sentiment, discussing how businesses can integrate ESG principles into their operations through sustainable supply chains, circular economy models, and community-driven projects. The discussion reinforced that cross-sector collaboration is not just beneficial but essential for scaling meaningful and measurable sustainability outcomes.The summit concluded with an inspiring keynote by Prof. Dr. Richard David Hames, urging businesses to remain committed to CSR and ESG as key drivers of long-term value. The event culminated in an awards ceremony recognizing outstanding contributions, with Guest of Honour Mr Vu Minh Ly, Vice Director of Resource and Environment Communication Centre, Ministry of Natural Resources and Environment and Dr Tran Quy, President of Vietnam Institute of Digital Economy Development.The Global CSR & ESG Summit 2025 concluded with a renewed commitment from industry leaders to scaling ESG initiatives and corporate social responsibility (CSR) practices that drive both environmental impact and business value. Delegates engaged in insightful discussions on integrating sustainability into corporate strategies, leveraging technology for ESG transparency, and forging partnerships to create long-term economic and social benefits. The summit provided actionable strategies for businesses to align profitability with purpose, ensuring that sustainability remains at the core of corporate decision-making.On the second day, delegates explored the Mekong Delta, gaining firsthand insights into the intersection of sustainable tourism, local economic empowerment, and environmental preservation. The tour included a scenic cruise along the Mekong River, visits to traditional riverside villages and coconut processing workshops, and a sampan ride through the region’s lush waterways. Delegates also experienced the cultural heritage of the Delta through local folk music, seasonal delicacies, and an authentic riverside meal, reinforcing the importance of preserving both ecological and cultural landscapes in sustainability efforts.Celebrating success! Recipients proudly display their awards at the 17th Annual Global CSR & ESG Summit and Awards 2025, recognizing their outstanding contributions to corporate social responsibility and environmental sustainability.Results for Global CSR & ESG Awards 2025Award Categories for 2025:Best Environmental Excellence AwardBest Community Programme AwardExcellence in Provision of Literacy & Education AwardEmpowerment of Women AwardBest Workplace PracticesCSR & ESG Leadership AwardBest CEOBest CFOBest Corporate Communications & Investors Relations TeamAdditionally, awards were given to companies excelling in their respective regions, including awards for Best in Thailand, Indonesia, Cambodia, Vietnam, Malaysia, and India.Best CEO Up to USD 500 Million in Market CapitalizationGold: BHG Retail REITPlatinum: Thanh Thanh Cong Bien Hoa Joint Stock CompanyUSD 1 Billion and above in Market CapitalizationPlatinum: Pertamina International ShippingBest CFO USD 1 Billion And Above in Market CapitalizationPlatinum: Pertamina International ShippingBest Corporate Communications & Investor Relations Team AwardUp to USD 500 Million Market CapitalizationSilver: BHG Retail REITGold: PT TBS Energi Utama Tbk (TBS)Platinum: Thanh Thanh Cong Bien Hoa Joint Stock CompanyUSD 1 Billion and above in Market CapitalizationPlatinum: Pertamina International ShippingBest Environmental Excellence AwardUp to USD 500 Million Market CapitalizationBronze: Hirdaramani Vietnam - Fashion Garments LimitedSilver: PT Pertamina EP Bunyu FieldGold: PT. Pertamina Patra Niaga AFT SepingganBank RakyatPlatinum: PT Pertamina EP Sangasanga FieldUSD 500 Million To USD 1 Billion Market CapitalizationSilver: PT Kalimantan Prima PersadaGold: PT Pertamina Patra Niaga AFT JuandaPlatinum: PT Pertamina EP Donggi Matindok FieldUSD 1 Billion And Above in Market CapitalizationBronze: PT Pertamina Patra Niaga Integrated Terminal SurabayaSilver: PT Pertamina Hulu MahakamPertamina International ShippingGold:Pertamina EP Zona 7PT Chandra Asri PacificThai Union GroupPTTEP IndonesiaPlatinum: Bridgestone Asia PacificBest Community Programme AwardUp to USD 500 Million Market CapitalizationBronze: PT Pertamina Hulu Sanga SangaSilver:EvermosHirdaramani Vietnam - Fashion Garments LimitedNagaWorld LimitedHengjaya MineralindoThanh Thanh Cong Bien Hoa Joint Stock CompanyGold:PT Pertamina EP Asset 4 Sukowati FieldPT Badak NGLPT Pertamina Patra Niaga FT MaosPertamina Patra Niaga Fuel Terminal RewuluPT Pertamina Patra Niaga Integrated Terminal SemarangPlatinum: PT Pertamina Patra Niaga Fuel Terminal TubanUSD 500 Million To USD 1 Billion Market CapitalizationBronze:Amazon Web ServicesPT Suprabari Mapanindo MineralSilver:PT Asmin Bara BronangPT Pertamina Patra Niaga Fuel Terminal SanggaranGold:Samsung VietnamAkzo Nobel VietnamPT Kalimantan Prima PersadaPlatinum: PT Pertamina Patra Niaga Fuel Terminal Tanjung GeremUSD 1 Billion And Above in Market CapitalizationBronze:Pertamina EP Papua FieldPT Pamapersada NusantaraPT Pertamina EP Donggi Matindok FieldPT Pertamina EP Sukowati FieldPT Pertamina Geothermal Energy Tbk Area UlubeluSilver:Bumi ResoucesPertamina EP Zona 7PT Chandra Asri PacificJOB Pertamina-Medco E&P Tomori SulawesiPertamina International ShippingGold:PT Pertamina Patra Niaga Integrated Terminal BanjarmasinSarawak Energy BerhadPT Pertamina Patra Niaga Fuel Terminal TarakanPT Pertamina Patra Niaga AFT SupadioCentral RetailPT Pertamina Patra Niaga Integrated Terminal PontianakPT Pertamina Patra Niaga Aviation Fuel Terminal BILPlatinum: Vinmec Healthcare SystemExcellence In Provisional Of Literacy & Education AwardLess Than USD 500 Million Market CapitalizationPlatinum: PT SAPTAINDRA SEJATI USD 500 Million To USD 1 Billion Market CapitalizationSilver: Amazon Web ServicesGold: PT Kalimantan Prima PersadaPlatinum: Samsung VietnamUSD 1 Billion And Above in Market CapitalizationGold: Pertamina International ShippingPlatinum: Sarawak Energy BerhadEmpowerment Of Women AwardUp to USD 500 Million Market CapitalizationSilver: DiageoGold: PT PLN Nusantara Power UP Gresik Platinum: Thanh Thanh Cong Bien Hoa Joint Stock CompanyUSD 500 Million to USD 1 Billion in Market CapitalizationGold: Pertamina International ShippingPlatinum: PT Kalimantan Prima PersadaUSD 1 Billion And Above in Market CapitalizationBronze: Bumi ResoucesSilver: Pertamina EP Zona 7Gold: PT Pertamina Hulu MahakamPlatinum: Sarawak Energy BerhadBest Workplace Practises Up to USD 500 Million Market CapitalizationPlatinum: Thanh Thanh Cong Bien Hoa Joint Stock CompanyUSD 1 Billion And Above in Market CapitalizationPlatinum: Vinmec Healthcare SystemProduct Excellence Award Up to USD 500 Million in Market CapitalizationPlatinum: CoMem Natural Cosmeceutics Join Stock CompanyUSD 1 Billion and above in Market CapitalizationPlatinum: Pertamina International ShippingCSR & ESG Leadership Award Up to USD 500 Million Market CapitalizationBronze: DiageoSilver: Asia Society for Social Improvement and Sustainable TransformationBHG Retail REIT Gold: CoMem Natural Cosmeceutics Join Stock CompanyHirdaramani Vietnam - Fashion Garments LimitedPlatinum: Thanh Thanh Cong Bien Hoa Joint Stock CompanyUSD 500 Million To USD 1 Billion Market CapitalizationPlatinum: Samsung VietnamUSD 1 Billion And Above in Market CapitalizationBronze: PT Indocement Tunggal Prakarsa TbkSilver: PT Chandra Asri PacificGold: Home Credit Vietnam Financial Company LimitedPlatinum: Advanta Enterprises Limited (AEL)Best Country Excellence – Best in CambodiaUSD 1 Billion And Above in Market CapitalizationPlatinum: NagaWorld LimitedBest Country Excellence – Best in ThailandUSD 1 Billion And Above in Market CapitalizationPlatinum: Thai Union GroupBest Country Excellence – Best In IndonesiaUp to USD 500 Million Market CapitalizationGold: PT PLN Indonesia Power UBP SuralayaPlatinum: PT Pertamina Geothermal Energy Tbk Area LahendongUSD 500 Million To USD 1 Billion Market CapitalizationPlatinum: PT Pertamina Hulu Energi West MaduraUSD 1 Billion And Above in Market CapitalizationGold: PT Kilang Pertamina Internasional Refinery Unit III PlajuPlatinum: PT Kalimantan Prima PersadaBest Country Excellence – Best in VietnamUp to USD 500 Million Market CapitalizationPlatinum: Thanh Thanh Cong Bien Hoa Joint Stock CompanyUSD 1 Billion And Above in Market CapitalizationPlatinum: Vinmec Healthcare SystemBest Country Excellence – Best in MalaysiaUp to USD 500 Million Market CapitalizationPlatinum: Tata Consultancy ServicesUSD 1 Billion And Above in Market CapitalizationPlatinum: Sarawak Energy BerhadBest Country Excellence – Best in IndiaUp to USD 500 Million Market CapitalizationPlatinum: Bridgestone Asia PacificFor media inquiries, please contact:Eric Khoo (Mr.)Head of Global Events and PartnershipsThe Pinnacle Group InternationalEmail: eric.khoo@pinnaclegroup.globalTel: +65 8383 2480 Copyright 2025 ACN Newswire via SeaPRwire.com.
KUALA LUMPUR, Mar 3, 2025 - (ACN Newswire via SeaPRwire.com) - The Tapping Tapir, Malaysia’s pioneering brand of naturally flavoured sparkling beverages, has introduced the latest addition to its gutC prebiotic drink range – Mix Berry. The new flavour was officially unveiled at the brand’s wellness-driven Valentine’s Day event at Pickle Nation, themed "Self-Love and Gut Love." This unique gathering blended fitness, mindfulness, and social connection, reinforcing the importance of gut health and self-care in daily life.The new gutC Mix Berry flavourSince its inception in 2013, The Tapping Tapir has been dedicated to crafting all-natural, additive-free beverages made from real fruit juices, spices, and herbs. The gutC range, designed to support digestive wellness, reflects the brand’s commitment to health-conscious innovation. Recognising that 70% of the immune system is linked to gut health, gutC offers a low-calorie, prebiotic-infused selection of refreshing drinks that seamlessly fit into modern lifestyles.The Peach and Grape gutC flavoursWith the launch of Mix Berry, gutC now features four unique flavours: Mix Berry, Peach, Grape, and Lychee – the latter being an exclusive offering at 7-Eleven outlets. Each variant is carefully formulated with prebiotics (Inulin & Apple Cider Vinegar) to support digestion, Vitamin C to strengthen the immune system, and less than 2g of sugar, keeping each can under 15 calories for a guilt-free, refreshing beverage experience.To mark the launch of Mix Berry, The Tapping Tapir hosted a special Valentine’s Day event at Pickle Nation, bringing together a diverse crowd of health enthusiasts, professional athletes, influencers, and brand partners for a day of self-care and gut health awareness. Attendees were treated to an array of immersive experiences that highlighted movement, mindfulness, and social connection.Participants took part in pickleball training sessions, where beginners were introduced to the fast-growing sport under expert guidance. Wellness expert Piyachai Teo led guided meditation and breathwork workshops, promoting relaxation and stress relief. The event also featured an invigorating ice bath recovery experience, showcasing the benefits of cold therapy for muscle recovery and mental clarity. Throughout the day, guests were invited to visit sampling stations, where they had the first taste of the new gutC Mix Berry, alongside other beverages from The Tapping Tapir.KOLs, celebrities, and Pickleball players at the gutC Mix Berry launch party, including Cik Manggis, Atita Haris, Intan Sarah, and Fad AnuarThe highlight of the event was a social pickleball tournament, which saw friendly competition among influencers, celebrities, and professional pickleball players. Among the notable attendees were Toi Sieu Ee, Malaysia’s No. 2-ranked pickleball player, alongside well-known personalities such as Cik Manggis, Mark O’Dea, Luqman Hafidz, and Intan Sarah. VIP guests from Diamond & Platinum, Christy Ng, and Pickle Fox were also present, adding to the vibrancy of the occasion.The competition concluded with participants vying for prizes in the Men’s Doubles and Mixed Doubles categories, with winners taking home RM500 cash prizes and a Six Zero Quartz Paddle, generously sponsored by Pickle Fox. Adding an element of glamour, Diamond & Platinum awarded a diamond necklace to the best-dressed guest, while two lucky winners received RM500 shopping vouchers.With the expanded gutC range, The Tapping Tapir continues to redefine healthy beverages in Malaysia. As a brand known for innovation and sustainability, it remains committed to sourcing high-quality natural ingredients from local farmers, minimising processing, and prioritising eco-friendly packaging. Widely available in premium retailers, cafés, and hotels, The Tapping Tapir is making it easier for consumers to embrace healthier, more responsible choices in their daily lives.For more information about gutC Mix Berry and upcoming events, visit www.thetappingtapir.com or follow The Tapping Tapir on its Facebook and Instagram pages.– End –About The Tapping Tapir:Founded in 2013, The Tapping Tapir is a proudly Malaysian brand specialising in all-natural sparkling sodas crafted from real fruit juices, herbs, and spices—free from artificial colours, flavours, or preservatives. Embracing the philosophy of “Refreshingly WILD,” the brand celebrates nature’s best ingredients to create bold, tropical flavours with a refreshing twist.Each beverage is enriched with Vitamin C and contains less than 5g of sugar, naturally sweetened with stevia leaf extract. Committed to quality and sustainability, The Tapping Tapir works closely with local farmers to source fresh ingredients while ensuring all products are Halal-certified.Headquartered in Seri Kembangan, Selangor, The Tapping Tapir’s beverages are available nationwide through leading retailers, wholesalers, and online platforms.For more information, visit www.thetappingtapir.com Copyright 2025 ACN Newswire via SeaPRwire.com.
Smaller "head" than the existing model, more efficient for handling subcompact mini vehicles・Domestic production allows for more focused after-sales service, as well as customization in a timely manner to meet customer needsTOKYO, Mar 4, 2025 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries Machinery Systems (MHI-MS), a part of Mitsubishi Heavy Industries (MHI) Group, has finalized domestic development of an autonomous car and vehicle transportation and storage system (hereafter referred to as "a vehicle transport robot") to move automobiles autonomously, and has started trial operations and endurance tests at its production plant.MHI-MS launched a collaborative project in 2021 with its partner Stanley Robotics (SR), a French venture firm, with the intention of importing the robots from France and marketing them domestically. It was later decided to produce a domestic model with Japanese specifications, allowing for more focused after-sales service in Japan, as well as customization in a timely manner to meet customer needs. With the switch to a domestic production policy, MHI-MS is pursuing measures for domestic production, including submitting applications and registering core patents in Japan.(Note1) The Japan market model has a smaller "head" than the existing model, this makes smaller vehicles easier to handle. In addition, at the customer's request, MHI-MS provides a "dress-up service" where the exterior of the head can be customized based on the customer's preference.MHI-MS has established a network of about 100 maintenance and other service bases in Japan. This hub network can also be used to provide service for vehicle transport robots. The adoption of domestic production will allow MHI-MS to provide "Made in Japan" quality with prompt after-sales service.Utilizing these robots for automated transport of finished vehicles(Note2) will greatly improve the work environment for workers engaged in vehicle transport on a regular basis, even in bad weather, extreme heat, and other harsh environments, while also responding to the demands of the logistics industry such as DX (digital transformation) and efficiency improvement.For automated valet parking(Note3) at commercial facilities, the robot will park the car in a vacant space, making it possible to turn the distant parking spaces that people tend to avoid into "close" parking spaces. It also eliminates the problem of drivers being distracted while looking for a vacant space, and causing an accident due to inattention. Further, CO2 emissions from driving vehicles through the site are suppressed, contributing to the realization of a society that is friendly to both people and the planet.Going forward, MHI-MS, as a pioneer in vehicle transport robots in Japan, will combine this innovative technology with the advanced intelligent transportation systems including traffic flow control technology, unmanned system monitoring and EV operation management technology developed by MHI Group to provide services that meet a wide range of customer needs.(1) See the following press release regarding the domestic registration of core patents. www.mhi.com/jp/news/24091101.html (Japanese)(2) The system can operate 24 hours a day year-round in automobile factories, ports, motor pools, and other compounds where vehicles need to be moved, solving the problem of a shortage of skilled drivers while at the same time delivering safe transport at low cost.(3) When the driver stops at a designated berth close to the facility, instead of having to find a parking space on their own, the vehicle transport robot moves the vehicle to a vacant space, taking over parking on behalf of the driver. The process is reversed when retrieving the vehicle, with the robot transporting the vehicle back to the berth at the time specified by the driver in advance using the smartphone app. For drivers, there is no need to find a parking space or park, and no concerns about brushing against the adjacent car when opening the door. For more information on the demonstration test of automated valet parking conducted at a commercial facility in Japan, see the following press releases. www.mhi.com/news/220613.htmlhttps://www.mhi.com/news/221118.htmlAbout MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2025 JCN Newswire via SeaPRwire.com.
TOKYO and CAMBRIDGE, Mass., Mar 4, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. and Biogen Inc. announced today that the Therapeutic Goods Administration (TGA) of Australia has confirmed the initial decision to decline the approval of humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody lecanemab (generic name) as a treatment for early Alzheimer’s disease (AD) (mild cognitive impairment due to AD and mild AD dementia).In October 2024, the TGA made the decision not to register lecanemab in Australia for the treatment of patients with early AD. In December 2024, Eisai requested reconsideration of the decision, proposing to the TGA the same apolipoprotein E4 (ApoE4) noncarrier and heterozygote indication that was agreed by the Medicines and Healthcare products Regulatory Agency (MHRA) and European Medicines Agency (EMA). In the course of the reconsideration of the initial decision, the TGA proposed an alternative narrow therapeutic indication only for ApoE4 noncarriers as an increasing number of ApoE4 alleles is a potential risk factor for ARIA. They did not agree that safety has been established for ApoE4 heterozygotes. Eisai proposed alternative indications, one of which was to maintain the ApoE4 noncarrier and heterozygote indication, but with heterozygotes treated in specialist centers and supervised by physicians with expertise in treatment of AD and monitoring for ARIA; however, the TGA rejected our proposal. “We are extremely disappointed and surprised by the TGA’s decision and understand that the AD community in Australia may also feel disheartened, especially given that eleven countries and regions across the globe have granted marketing authorization. We tried earnestly to reach a compromise with the TGA on an indication that would adequately represent the data in the application but were unfortunately unsuccessful at this time,” said Lynn Kramer, M.D., Chief Clinical Officer at Eisai. “The TGA proposed a narrow indication that would limit access to only ApoE4 noncarriers. This indication would deny approximately two-thirds (~70%) of all potentially eligible patients access to a treatment that could slow the progression of AD. Eisai believes ApoE4 heterozygote carriers should at least also have access to lecanemab given the similar benefit-risk profile to the noncarrier population. Therefore, we could not accept this restrictive indication as it is not patient-centric. Given this outcome, we are deeply concerned that Australians living with Alzheimer’s disease will not have access to a treatment that slows the progression of early Alzheimer’s disease by targeting its underlying causes. Eisai remains committed to ensuring eligible Australians with early Alzheimer’s disease can access lecanemab and is exploring options to achieve this, including potentially seeking review by the Administrative Review Tribunal.”In Australia, the number of people living with dementia was estimated to be approximately 411,000 in 2023, and is reported to increase to approximately 849,000 by 2058.1 AD is considered the most common cause of dementia, typically accounting for 60-70% of cases.2 AD progresses over time in stages with increasingly severe symptoms that greatly impact not only those who are living with AD, but also their loved ones, care partners and society. There is a significant unmet need for new treatment options that slow down the progression of AD from its early stage.=Aβ which is involved in the onset of AD, gradually aggregates in the brain 15 to 20 years before symptoms appear, eventually forming insoluble plaques, a pathological feature of AD. AD is a progressive, relentless disease caused by a continuous underlying neurotoxic process that begins before and continues after plaque removal.3,4,5 Only lecanemab works to fight AD in two ways: continuously clearing protofibrils* ,the most toxic Aβ species, and rapidly clearing plaque. This mechanism has been shown to reduce the rate of disease progression and to slow cognitive and functional decline. Lecanemab has been approved in the U.S., Japan, China, South Korea, Hong Kong, Israel, the United Arab Emirates, the United Kingdom, Mexico, Macau and Oman. Regulatory filings for the treatment have been made in the EU and 17 other countries and regions. In the EU, in February 2025, the Committee for Medicinal Products for Human Use reaffirmed its positive opinion for lecanemab in early AD, adopted in November 2024, and the European Commission is proceeding with the decision-making process for lecanemab’s marketing authorization.Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.*Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.6Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.7About lecanemabLecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).Lecanemab is approved in the U.S.,8 Japan,9 China,10 South Korea,11 Hong Kong,12 Israel,13 the United Arab Emirates,14the United Kingdom,15 Mexico16, Macau and Oman. Eisai has submitted applications for approval of lecanemab in 17 countries and regions. In the EU, in February 2025, the Committee for Medicinal Products for Human Use reaffirmed its positive opinion for lecanemab in early AD, adopted in November 2024, and the European Commission is proceeding with the decision-making process for lecanemab’s marketing authorization. In January 2025, the supplemental Biologics License Application (sBLA) for intravenous (IV) maintenance dosing of the treatment was approved in the U.S. After an 18 months initiation phase with once every two weeks of dosing, a transition to the maintenance dosing regimen of 10 mg/kg once every four weeks or continuing 10 mg/kg once every two weeks may be considered. Additionally, the U.S. Food and Drug Administration (FDA) accepted Eisai’s Supplemental Biologics License (BLA) for the LEQEMBI subcutaneous autoinjector for weekly maintenance dosing in January 2025 and set a PDUFA action date for August 31, 2025.Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.About the Collaboration between Eisai and Biogen for ADEisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.About the Collaboration between Eisai and BioArctic for ADSince 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.About Eisai Co., Ltd.Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai. Co., Ltd.), us.eisai.com (for U.S. headquarters: Eisai, Inc.) or www.eisai.eu (for Europe, Middle East, Africa, Russia, Australia and New Zealand headquarters: Eisai Europe Ltd.), and connect with us on X (global and U.S), LinkedIn (for global, U.S.and EMEA) and Facebook (global).About BiogenFounded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.The company routinely posts information that may be important to investors on its website at www.biogen.com. Follow Biogen on social media – Facebook, LinkedIn, X, YouTube Biogen Safe HarborThis news release contains forward-looking statements, including about the potential clinical effects of lecanemab; the potential benefits, safety and efficacy of lecanemab; potential regulatory discussions, submissions and approvals and the timing thereof; the treatment of Alzheimer's disease; the anticipated benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would,” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements. These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans and prospects relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; our ability to effectively implement our corporate strategy; the successful execution of our strategic and growth initiatives, including acquisitions; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our subsequent reports on Form 10-Q and Form 10-K, in each case including in the sections thereof captioned “Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in our subsequent reports on Form 8-K. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.References(1) Dementia in Australia https://www.aihw.gov.au/reports/dementia/dementia-in-aus/contents/population-health-impacts-of-dementia/prevalence-of-dementia(New Window)(2) World Health Organization. Dementia Fact Sheet. March 2023. Available at: https://www.who.int/news-room/fact-sheets/detail/dementia(New Window).(3) Eisai presents full results of lecanemab Phase 3 confirmatory Clarity AD study for early Alzheimer's disease at Clinical Trials on Alzheimer's Disease (CTAD) conference. Available at: https://www.eisai.co.jp/news/2022/news202285.html(New Window)(4) van Dyck, H., et al. Lecanemab in Early Alzheimer’s Disease. New England Journal of Medicine. 2023;388:9-21. https://www.nejm.org/doi/full/10.1056/NEJMoa2212948(New Window).(5) Hampel H, Hardy J, Blennow K, et al. The amyloid-β pathway in Alzheimer’s disease. Mol Psychiatry. 2021;26(10):5481-5503.(6) Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi:10.1038/s41467-021-23507-z(7) Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.(8) U.S. Food and Drug Administration. 2023. FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval. Last accessed: October 2024.(9) Reuters. 2023. Japan approves Alzheimer's treatment Leqembi by Eisai and Biogen. Last accessed: October 2024.(10) The Pharma Letter. 2024. Brief - Alzheimer drug Leqembi now approved in China. Last accessed: October 2024.(11) Pharmaceutical Technology. 2024. South Korea's MFDS approves Eisai-Biogen's LEQEMBI for Alzheimer's. Last accessed: October 2024.(12) Pharmaceutical Technology. 2024. Hong Kong approves Leqembi for Alzheimer's treatment. Last accessed: October 2024.(13) BioSpace. 2024. Leqembi approved for the treatment of Alzheimer's disease in Israel. Last accessed: October 2024.(14) United Arab Emirates Ministry of Health & Prevention. 2024. Registered Medical Product Directory. Leqembi. Last accessed: October 2024.(15) BioSpace. 2024. Leqembi authorized for early Alzheimer's disease in Great Britain. Last accessed: October 2024.(16) COFEPRIS authorizes innovative treatment for Alzheimer’s patients. Available at: https://bit.ly/3OKks6Y(New Window). Last accessed: December 2024.MEDIA CONTACTSEisaiEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120Eisai Europe, Ltd.(UK, Europe, Australia, New Zealand and Russia)EMEA Communications Department+44 (0) 797 487 9419Emea-comms@eisai.netEisai Inc. (U.S.)Libby Holman+1-201-753-1945Libby_Holman@eisai.comEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120Eisai Europe, Ltd.(UK, Europe, Australia, New Zealand and Russia)EMEA Communications Department+44 (0) 797 487 9419Emea-comms@eisai.netEisai Inc. (U.S.)Libby Holman+1-201-753-1945Libby_Holman@eisai.comBiogen Inc.Jack Cox+ 1-781-464-3260public.affairs@biogen.com Copyright 2025 JCN Newswire via SeaPRwire.com.
TOKYO, March 4, 2025 - (JCN Newswire via SeaPRwire.com) - Prideone Entertainment Co., Ltd. (Headquarters: Shibuya, Tokyo; CEO: Yasushi Akutagawa) has announced the concept for a new film tentatively titled "Fellers" to mark the 80th anniversary of the post-war era.Akutagawa said, "Fellers is an epic historical spectacle that looks behind the scenes of history from the perspective that it was an American officer, Bonner Fellers, and a group of Christians who saved the Emperor immediately after World War II."Akutagawa, who was the original planner and producer of the 2012 American-Japanese film Emperor (with a production budget of 3 billion yen), also focused on Bonner Fellers in that film. However, various interpretations were incorporated, and the final cut differed considerably from the original idea. The film became a love story between Bonner Fellers, played by Matthew Fox, and an imaginary Japanese lover.In response, various individuals, including Yoshiko Isshiki, former chairperson of Keisen Women's School, strongly suggested that a true-to-history depiction of Fellers be made in this 80th year since the end of the war. This led Akutagawa to create a new film from the fresh perspective. A Japanese director has been chosen for the project, and an original script based on historical facts has already been completed.Post-war Japan began on August 30, 1945, when General Douglas MacArthur, the Supreme Commander of the Allied Powers, landed in Japan and started the full-scale American occupation. MacArthur initiated mass arrests of war criminals and began activities to prosecute them. In the United States, there were strong calls from both the government and public to prosecute the Emperor. On the other hand, MacArthur considered the construction of an "anti-communist bulwark" in the Far East to be of utmost importance. He also eyed a future political career and a potential presidential run, so he felt that he needed to achieve success in post-war governance of Japan at all costs. From this viewpoint, he believed that arresting and executing the Emperor would gain him popular support. MacArthur ordered his subordinates to gather evidence that the Emperor had played a decisive role in Japan’s decision to go to war, including the attack on Pearl Harbor. Meanwhile, Bonner Fellers, an American officer with a deep knowledge of Japan, was tasked by MacArthur to investigate. Fellers, who had become acquainted with Yuri Isshiki before the war, was persuaded by the writings of Lafcadio Hearn, a renowned writer he was introduced to by Yuri, and believed that the Emperor should not be executed. Fellers immediately began searching for the whereabouts of Yuri and her mentor, Michi Kawai. This marked the beginning of a grand political drama and historical spectacle that would lay the foundations for what is now modern Japan. Had these events not unfolded as they did, Japan as we know it might not have existed.Currently, the project is progressing with filming planned for 2027 (in Japan and New Zealand) and release in the fall of 2028. Prideone Entertainment is forecasting a production budget of 4 billion yen, with an additional 1 billion yen for prints and advertising, and is seeking financing options.About the Producer and Executive Producer, Yasushi Akutagawa:Born April 3, 1956, in Kumamoto City, Kumamoto Prefecture. He graduated from the Film Department of the College of Art at Nihon University. Akutagawa started making 8mm films while attending Kumamoto Prefectural Seiseiko High School and decided to pursue a career in film production at university. After graduation, he worked at a major advertising agency before founding Prideone Entertainment Co., Ltd. Since then, he has been involved in producing a wide range of projects in film, television, theater, and radio.Notable Works:- 1991: Futari (Starring: Hikari Ishida) Directed by Nobuhiko Obayashi- 1995: Ashita (Starring: Kaori Takahashi, Yasufumi Hayashi) Directed by Nobuhiko Obayashi- 1998: Kaze no Uta ga Kikitai (Starring: Ryo Amamiya, Yuri Nakae, Tokyo International Film Festival Special Invitation) Directed by Nobuhiko Obayashi- 1999: Ano Natsu no Hi (Starring: Keiju Kobayashi, Yubari International Fantastic Film Festival Special Invitation) Directed by Nobuhiko Obayashi- 2000: Den'en no Ytsu (Starring: Tomokazu Miura, Mitsuko Baisho, Tokyo International Film Festival Special Invitation) Directed by Keisuke Kawahara- 2013: Emperor (Starring: Matthew Fox) Directed by Peter WebberFor inquiries:Prideone Entertainment Co., Ltd.https://yasushi-akutagawa.studio.site/PR: Tsukiokaakidiginfo@gmail.com Copyright 2025 JCN Newswire via SeaPRwire.com.
TOKYO, Mar 5, 2025 - (JCN Newswire via SeaPRwire.com) - Sato Pharmaceutical Co., Ltd. and Eisai Co., Ltd. announced today that they will conclude their co-promotion based on the co-promotion agreement in Japan regarding the orally-administered antifungal agent NAILIN® Capsules 100 mg (generic name: fosravuconazole) which is manufactured and marketed by Sato Pharmaceutical, as of March 31, 2025. Sato Pharmaceutical and Eisai have concluded a new agreement, under which Eisai will carry out promotional activities for this drug and transfer operations to Sato Pharmaceutical during a transition period from April 1, 2025, to March 31, 2026.NAILIN® Capsules 100 mg have been marketed by Sato Pharmaceutical in Japan since July 2018, with a co-promotion agreement between both companies. However, following the conclusion of the co- promotion agreement and the signing of a new agreement, Sato Pharmaceutical will independently conduct promotions starting from April 2026, following a transition period. Additionally, inrelation to this matter, Sato Pharmaceutical will pay Eisai a lump sum.About fosravuconazoleFosravuconazole is a new oral antifungal component developed by Eisai. Fosravuconazole is a prodrug that improves thesolubility and bioavailability of ravuconazole, the main active ingredient. When administered to humans, it is rapidly converted toravuconazole. Ravuconazole demonstrates antifungal activity by inhibiting ergosterol biosynthesis, a membrane component of fungal cells.In Japan, Seren Pharmaceuticals Inc., which was granted exclusive development and commercialization of this drug by Eisai, has been advancing its development for onychomycosis with Sato Pharmaceutical. Sato Pharmaceutical obtained manufacturing and marketing approval in January 2018, and since July 2018, it has been marketed as Nailin Capsule 100mg.Sato Pharmaceutical and Eisai entered into a license agreement in July 2024, under which Sato Pharmaceutical will undertake the development and commercialization in Asia and Oceania* for fungal diseases.*10 ASEAN member states, Australia, New Zealand, South Korea, TaiwanMedia InquiriesEisai Co., Ltd.Public Relations Department TEL: +81 (0)3-3817-5120Sato Pharmaceutical Co., Ltd. Public Relations Department TEL: +81-(0)3-5412-7354 Copyright 2025 JCN Newswire via SeaPRwire.com.
